Perspectives on Probiotics and Bronchopulmonary Dysplasia

Area of Science:

• Neonatal Medicine
• Microbiology
• Pulmonology

Background:

• Bronchopulmonary dysplasia (BPD) is a significant chronic respiratory disease in preterm infants, leading to high morbidity and healthcare costs.
• Emerging evidence links lung microbiota dysbiosis to the development and progression of BPD.
• Current therapeutic strategies for BPD do not fully address the role of lung microbiota.

Purpose of the Study:

• To review the current understanding of lung microbiota dysbiosis in BPD.
• To explore the potential of probiotic interventions for BPD treatment.
• To provide insights into novel therapeutic approaches targeting the gut-lung axis in BPD.

Main Methods:

• Literature review of studies on BPD, lung microbiota, and probiotics.
• Analysis of evidence regarding the gut-lung axis in respiratory diseases.
• Synthesis of findings on probiotic mechanisms and their relevance to BPD.

Main Results:

• Lung microbiota dysbiosis is increasingly recognized as a factor in BPD pathogenesis.
• Probiotics demonstrate potential for modulating microbiota, reducing inflammation, and supporting the gut-lung axis.
• Evidence suggests probiotics could offer a novel therapeutic avenue for BPD.

Conclusions:

• Lung microbiota dysbiosis plays a role in BPD.
• Probiotics represent a promising, yet under-investigated, therapeutic strategy for BPD.
• Further research into probiotic applications is warranted to improve BPD management.